- R&D Pipeline
- Season 2 (2021-2030)
| Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
|---|---|---|---|---|---|---|---|
| 1 | Development of BFD1R, an immunomodulatory Live Biotherapeutic Products(LBP) for rheumatoid arthritis | ||||||
| Others | Rheumatoid Arthritis | Gut (Gut.joint axis | Preclinical | BIFIDO Co., Ltd | RS-2023-00258617 | ||
| 2 | Therapeutic exosome development in Inflammatory Bowel Disease (IBD) with CARD9/TRIM62 Protein-Protein Interaction (PPI) inhibition activity | ||||||
| Others | Inflammatory Bowel Disease | CARD9, TRIM62 | Hit | ILIAS Biologics Inc. | HN22C0582 | ||
| 3 | Nonclinical Study for Treatment of IRI Using Bilirubin Nanoparticle (Brixelle) | ||||||
| Others | Ischemia reperfusion injury | ROS | Preclinical | BILIX | HN21C0947 | ||
| 4 | Development of functional hyaluronic acid nanoparticle lead compounds for treatment of skin inflammation | ||||||
| Others | Psoriasis, Contact dermatitis | Hyaluronic acid | Lead | Ajou University | HN21C0958 | ||